Novel Approaches to Target MECOM/EVI1 in AML

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements.
Epistemonikos ID: 646c6c1706d8d1cf9b9f20b412444c8567602bc2
First added on: May 14, 2024